Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT

This phase II trial studies how well gruticibart works in reducing the incidence of catheter-related thrombosis (CRT) blood clots in patients with a central venous catheter (CVC) inserted. Many patients develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Gruticibart, a type of drug called a monoclonal antibody, may prevent blood clots caused by a catheter.

NCT Number	NCT07498517
Lead Sponsor	OHSU Knight Cancer Institute Collaborators: National Heart, Lung, and Blood Institute (NHLBI), Oregon Health and Science University
Conditions	Thrombosis
Enrollment	90 participants
Start Date	2026-02-28
Primary Completion	2029-02-02 (estimated)
Study Completion	2029-10-02 (estimated)
Updated on ClinicalTrials.gov	2026-03-27